 CAMBRIDGE, Mass., Oct. 07, 2021 GLOBE NEWSWIRE -- Editas Medicine, Inc. Nasdaq: EDIT, a leading genome editing company, today announced that the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for Immunotherapy of Cancer SITC 36th Annual Meeting being held in Washington, D.C., and virtually, November 10-14, 2021. 